Obchod Aclaris Therapeutics Inc - ACRS CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Rozpätie | 0.07 | ||||||||
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.030779% | ||||||||
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | -0.013666% | ||||||||
Nočný poplatok | 22:00 (UTC) | ||||||||
Minimálne množstvo na obchodovanie | 1 | ||||||||
Mena | USD | ||||||||
Marža | 20% | ||||||||
Burza cenných papierov | United States of America | ||||||||
Provízia pri predaji | 0% |
*Information provided by Capital.com
Predchádzajúce Zavrieť* | 14.01 |
Otvoriť* | 14.02 |
1-ročná zmena* | -1.68% |
Denný rozsah* | 13.84 - 14.36 |
Rozsah 52 týždňov | 9.84-18.96 |
Priemerný objem (10 dní) | 648.07K |
Priemerný objem (3 mesiace) | 8.12M |
Trhová kapitalizácia | 955.57M |
Pomer P/E | -100.00K |
Zdieľa mimoriadne | 66.68M |
Výnosy | 23.50M |
EPS | -1.29 |
Dividenda (udalosť %) | N/A |
Beta | 0.54 |
Ďalší dátum zárobku | Feb 22, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 14.32 | 0.74 | 5.45% | 13.58 | 14.37 | 13.50 |
Jun 28, 2022 | 14.01 | -0.96 | -6.41% | 14.97 | 15.26 | 13.98 |
Jun 27, 2022 | 15.06 | 0.68 | 4.73% | 14.38 | 15.72 | 14.38 |
Jun 24, 2022 | 14.41 | -1.42 | -8.97% | 15.83 | 16.16 | 14.17 |
Jun 23, 2022 | 15.81 | 0.28 | 1.80% | 15.53 | 16.17 | 15.13 |
Jun 22, 2022 | 15.43 | 0.01 | 0.06% | 15.42 | 16.16 | 15.41 |
Jun 21, 2022 | 15.93 | 0.35 | 2.25% | 15.58 | 16.52 | 15.58 |
Jun 17, 2022 | 15.57 | 0.97 | 6.64% | 14.60 | 15.84 | 14.60 |
Jun 16, 2022 | 14.76 | 0.77 | 5.50% | 13.99 | 14.88 | 13.99 |
Jun 15, 2022 | 14.72 | 0.89 | 6.44% | 13.83 | 14.80 | 13.80 |
Jun 14, 2022 | 13.95 | 1.16 | 9.07% | 12.79 | 14.00 | 12.65 |
Jun 13, 2022 | 12.91 | -0.88 | -6.38% | 13.79 | 13.99 | 12.41 |
Jun 10, 2022 | 14.39 | -0.22 | -1.51% | 14.61 | 14.90 | 14.17 |
Jun 9, 2022 | 15.04 | 0.06 | 0.40% | 14.98 | 15.48 | 14.98 |
Jun 8, 2022 | 15.42 | 0.41 | 2.73% | 15.01 | 15.86 | 15.01 |
Jun 7, 2022 | 15.39 | 1.36 | 9.69% | 14.03 | 15.45 | 14.03 |
Jun 6, 2022 | 14.71 | -0.02 | -0.14% | 14.73 | 14.94 | 14.44 |
Jun 3, 2022 | 14.70 | 0.48 | 3.38% | 14.22 | 14.90 | 14.08 |
Jun 2, 2022 | 14.41 | 1.06 | 7.94% | 13.35 | 14.94 | 13.35 |
Jun 1, 2022 | 13.32 | 0.66 | 5.21% | 12.66 | 13.43 | 12.59 |
Aclaris Therapeutics Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Celkové príjmy | 0 | 1.683 | 6.151 | 4.227 | 6.482 | 6.761 |
Výnosy | 0 | 1.683 | 6.151 | 4.227 | 6.482 | 6.761 |
Celkové prevádzkové náklady | 48.567 | 74.106 | 90.931 | 115.285 | 57.394 | 96.484 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 15.091 | 33.109 | 25.761 | 27.827 | 20.53 | 23.619 |
Výskum a vývoj | 33.476 | 39.79 | 60.841 | 64.899 | 31.731 | 43.813 |
Prevádzkový príjem | -48.567 | -72.423 | -84.78 | -111.058 | -50.912 | -89.723 |
Iné, Net | 0.488 | 2.07 | 2.676 | -2.484 | -0.424 | -1.142 |
Čistý príjem pred zdanením | -48.079 | -70.353 | -82.104 | -113.542 | -51.336 | -90.865 |
Čistý príjem po zdanení | -48.079 | -70.36 | -82.104 | -113.542 | -51.154 | -90.865 |
Čistý príjem pred extra. Položky | -48.079 | -70.36 | -82.104 | -113.542 | -51.154 | -90.865 |
Čistý príjem | -48.079 | -68.523 | -132.738 | -161.354 | -51.015 | -90.865 |
Total Adjustments to Net Income | 0 | 0 | ||||
Príjem k dispozícii bežnému Extra. Položky | -48.079 | -70.36 | -82.104 | -113.542 | -51.154 | -90.865 |
Príjem k dispozícii bežnému vr. Extra. Položky | -48.079 | -68.523 | -132.738 | -161.354 | -51.015 | -90.865 |
Zriedený čistý príjem | -48.079 | -68.523 | -132.738 | -161.354 | -51.015 | -90.865 |
Zriedený vážený priemer akcií | 21.4157 | 28.1024 | 32.9098 | 41.3239 | 42.5393 | 56.7306 |
Zriedený EPS s výnimkou mimoriadnych položiek | -2.24503 | -2.5037 | -2.49482 | -2.74761 | -1.20251 | -1.60169 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Zriedený normalizovaný EPS | -2.24503 | -2.5037 | -2.49482 | -2.29983 | -1.20251 | -1.17267 |
Náklady na výnosy, celkom | 1.207 | 4.329 | 4.055 | 5.133 | 4.713 | |
Hrubý zisk | 0.476 | 1.822 | 0.172 | 1.349 | 2.048 | |
Celkom mimoriadne položky | 1.837 | -50.634 | -47.812 | 0.139 | 0 | |
Depreciation / Amortization | 0 | 0 | ||||
Nezvyčajné výdavky (príjem) | 0 | 18.504 | 0 | 24.339 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Celkové príjmy | 1.777 | 1.824 | 1.659 | 1.501 | 1.453 |
Výnosy | 1.777 | 1.824 | 1.659 | 1.501 | 1.453 |
Náklady na výnosy, celkom | 1.202 | 1.263 | 1.099 | 1.149 | 1.155 |
Hrubý zisk | 0.575 | 0.561 | 0.56 | 0.352 | 0.298 |
Celkové prevádzkové náklady | 30.306 | 19.83 | 21.954 | 24.394 | 20.36 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 4.827 | 5.87 | 5.979 | 6.943 | 6.099 |
Výskum a vývoj | 7.838 | 7.897 | 13.976 | 14.102 | 14.306 |
Nezvyčajné výdavky (príjem) | 16.439 | 4.8 | 0.9 | 2.2 | -1.2 |
Prevádzkový príjem | -28.529 | -18.006 | -20.295 | -22.893 | -18.907 |
Iné, Net | -0.225 | -0.155 | -0.851 | 0.089 | 0.118 |
Čistý príjem pred zdanením | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Čistý príjem po zdanení | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Čistý príjem pred extra. Položky | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Celkom mimoriadne položky | 0 | 0 | 0 | 0 | |
Čistý príjem | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Príjem k dispozícii bežnému Extra. Položky | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Príjem k dispozícii bežnému vr. Extra. Položky | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Zriedený čistý príjem | -28.754 | -18.161 | -21.146 | -22.804 | -18.789 |
Zriedený vážený priemer akcií | 50.3378 | 53.9684 | 61.2193 | 61.2772 | 61.431 |
Zriedený EPS s výnimkou mimoriadnych položiek | -0.57122 | -0.33651 | -0.34541 | -0.37214 | -0.30586 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Zriedený normalizovaný EPS | -0.24465 | -0.24757 | -0.33071 | -0.33624 | -0.32539 |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Celkové aktíva | 138.556 | 200.221 | 179.499 | 83.803 | 57.493 | 205.032 |
Hotovosť a krátkodobé investície | 137.222 | 193.857 | 167.972 | 75.015 | 54.131 | 191.414 |
Hotovosť a ekvivalenty | 30.171 | 20.202 | 57.019 | 35.937 | 22.063 | 27.349 |
Krátkodobé investície | 107.051 | 173.655 | 110.953 | 39.078 | 32.068 | 164.065 |
Prepaid Expenses | 1.334 | 5.883 | 4.802 | 3.118 | 2.59 | 12.995 |
Total Assets | 176.085 | 243.509 | 275.566 | 98.297 | 70.784 | 251.211 |
Property/Plant/Equipment, Total - Net | 0.481 | 2.159 | 2.287 | 7.203 | 5.783 | 4.772 |
Property/Plant/Equipment, Total - Gross | 0.607 | 2.639 | 3.609 | 9.749 | 9.517 | 9.968 |
Accumulated Depreciation, Total | -0.126 | -0.48 | -1.322 | -2.546 | -3.734 | -5.196 |
Long Term Investments | 36.912 | 14.997 | 34.242 | |||
Other Long Term Assets, Total | 0.136 | 0.279 | 68.003 | 0.092 | 0.385 | 0.117 |
Total Current Liabilities | 6.223 | 12.762 | 27.342 | 22.432 | 14.874 | 22.931 |
Accounts Payable | 2.845 | 7.822 | 14.755 | 9.917 | 5.254 | 9.985 |
Accrued Expenses | 1.809 | 3.01 | 6.071 | 4.015 | 4.574 | 5.082 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.569 | 1.788 | 6.374 | 8.389 | 5.046 | 7.864 |
Total Liabilities | 6.595 | 18.247 | 60.442 | 28.385 | 33.134 | 53.87 |
Total Long Term Debt | 0 | 0 | 29.914 | 0.021 | 10.653 | 0 |
Other Liabilities, Total | 0.372 | 4.936 | 2.637 | 5.383 | 7.24 | 30.572 |
Total Equity | 169.49 | 225.262 | 215.124 | 69.912 | 37.65 | 197.341 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0 | 0 | 0 | 0.00042 | 0.00045 | 0.001 |
Additional Paid-In Capital | 260.671 | 384.943 | 507.366 | 523.505 | 542.286 | 792.971 |
Retained Earnings (Accumulated Deficit) | -90.912 | -159.435 | -292.173 | -453.527 | -504.542 | -595.407 |
Other Equity, Total | -0.269 | -0.246 | -0.069 | -0.06642 | -0.09445 | -0.224 |
Total Liabilities & Shareholders’ Equity | 176.085 | 243.509 | 275.566 | 98.297 | 70.784 | 251.211 |
Total Common Shares Outstanding | 26.0592 | 30.8565 | 41.2107 | 41.4856 | 45.1093 | 61.2285 |
Pohľadávky celkom, netto | 0.481 | 0.563 | 0.704 | 0.772 | 0.623 | |
Accounts Receivable - Trade, Net | 0.481 | 0.563 | 0.704 | 0.772 | 0.623 | |
Goodwill, Net | 18.504 | 18.504 | 0 | |||
Intangibles, Net | 7.349 | 7.273 | 7.199 | 7.123 | 7.048 | |
Current Port. of LT Debt/Capital Leases | 0.142 | 0.142 | 0.111 | 0 | ||
Deferred Income Tax | 0.549 | 0.549 | 0.549 | 0.367 | 0.367 | |
Total Inventory | 0 | 0 | ||||
Other Current Assets, Total | 6.162 | 4.966 | ||||
Long Term Debt | 29.914 | 0 | 10.653 | 0 | ||
Capital Lease Obligations | 0.021 | 0 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Celkové aktíva | 134.501 | 241.261 | 205.782 | 205.032 | 190.881 |
Hotovosť a krátkodobé investície | 128.295 | 231.674 | 197.882 | 191.414 | 179.622 |
Hotovosť a ekvivalenty | 35.267 | 113.447 | 53.602 | 27.349 | 36.342 |
Krátkodobé investície | 93.028 | 118.227 | 144.28 | 164.065 | 143.28 |
Pohľadávky celkom, netto | 0.817 | 0.939 | 0.811 | 0.623 | 0.633 |
Accounts Receivable - Trade, Net | 0.817 | 0.939 | 0.811 | 0.623 | 0.633 |
Prepaid Expenses | 5.389 | 8.648 | 7.089 | 12.995 | 10.626 |
Total Assets | 161.399 | 288.046 | 263.494 | 251.211 | 226.527 |
Property/Plant/Equipment, Total - Net | 5.385 | 5.077 | 4.785 | 4.772 | 4.531 |
Property/Plant/Equipment, Total - Gross | 9.517 | 9.569 | 9.625 | 9.968 | 10.056 |
Accumulated Depreciation, Total | -4.132 | -4.492 | -4.84 | -5.196 | -5.525 |
Intangibles, Net | 7.105 | 7.086 | 7.067 | 7.048 | 7.03 |
Long Term Investments | 14.362 | 34.503 | 45.735 | 34.242 | 23.955 |
Other Long Term Assets, Total | 0.046 | 0.119 | 0.125 | 0.117 | 0.13 |
Total Current Liabilities | 14.505 | 14.916 | 17.839 | 22.931 | 16.726 |
Accounts Payable | 7.292 | 4.244 | 7.564 | 9.985 | 8.121 |
Accrued Expenses | 1.982 | 2.569 | 3.514 | 5.082 | 2.9 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 5.231 | 8.103 | 6.761 | 7.864 | 5.705 |
Total Liabilities | 49.105 | 54.231 | 46.913 | 53.87 | 46.328 |
Total Long Term Debt | 10.692 | 10.731 | 0 | 0 | 0 |
Long Term Debt | 10.692 | 10.731 | 0 | 0 | 0 |
Deferred Income Tax | 0.367 | 0.367 | 0.367 | 0.367 | 0.367 |
Other Liabilities, Total | 23.541 | 28.217 | 28.707 | 30.572 | 29.235 |
Total Equity | 112.294 | 233.815 | 216.581 | 197.341 | 180.199 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00052 | 0.001 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 645.73 | 785.455 | 789.186 | 792.971 | 795.366 |
Retained Earnings (Accumulated Deficit) | -533.296 | -551.457 | -572.603 | -595.407 | -614.196 |
Other Equity, Total | -0.14052 | -0.184 | -0.003 | -0.224 | -0.972 |
Total Liabilities & Shareholders’ Equity | 161.399 | 288.046 | 263.494 | 251.211 | 226.527 |
Total Common Shares Outstanding | 52.0817 | 61.205 | 61.2267 | 61.2285 | 61.7375 |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Čistý príjem/Počiatočná čiara | -48.079 | -68.523 | -132.738 | -161.354 | -51.015 | -90.865 |
Hotovosť z prevádzkovej činnosti | -34.603 | -54.663 | -100.811 | -96.445 | -38.633 | -52.134 |
Hotovosť z prevádzkovej činnosti | 0.12 | 0.402 | 1.879 | 6.409 | 1.324 | 0.923 |
Bezhotovostné položky | 9.104 | 14.43 | 20.61 | 61.203 | 13.6 | 39.151 |
Zmeny pracovného kapitálu | 4.252 | 0.865 | 9.438 | -2.703 | -2.36 | -1.343 |
Peniaze z investičných činností | -61.903 | -55.692 | 9.367 | 105.679 | 6.387 | -167.632 |
Kapitálové výdavky | -0.232 | -1.235 | -1.356 | -1.613 | -0.453 | -0.308 |
Ostatné investičné položky peňažných tokov, celkom | -61.671 | -54.457 | 10.723 | 107.292 | 6.84 | -167.324 |
Hotovosť z finančných činností | 116.826 | 100.386 | 128.261 | -30.316 | 18.372 | 225.052 |
Vydanie (vyradenie) zásob, netto | 116.826 | 100.464 | 100.782 | 0.207 | 7.807 | 239.659 |
Čistá zmena v hotovosti | 20.32 | -9.969 | 36.817 | -21.082 | -13.874 | 5.286 |
Deferred Taxes | -1.837 | 0 | 0 | -0.182 | 0 | |
Financovanie položiek peňažných tokov | 0 | 28.127 | -0.211 | -3.124 | ||
Vydanie (vyradenie) dlhu, netto | -0.078 | -0.648 | -30.523 | 10.776 | -11.483 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -28.754 | -46.915 | -68.061 | -90.865 | -18.789 |
Cash From Operating Activities | -12.232 | -24.453 | -35.059 | -52.134 | -20.969 |
Cash From Operating Activities | 0.288 | 0.535 | 0.726 | 0.923 | 0.208 |
Non-Cash Items | 19.114 | 27.746 | 33.1 | 39.151 | 1.146 |
Changes in Working Capital | -2.88 | -5.819 | -0.824 | -1.343 | -3.534 |
Cash From Investing Activities | -75.314 | -120.784 | -158.456 | -167.632 | 29.932 |
Capital Expenditures | 0 | -0.052 | -0.108 | -0.308 | -0.164 |
Other Investing Cash Flow Items, Total | -75.314 | -120.732 | -158.348 | -167.324 | 30.096 |
Cash From Financing Activities | 100.75 | 236.621 | 225.054 | 225.052 | 0.03 |
Financing Cash Flow Items | -3.014 | -3.038 | -3.122 | -3.124 | -0.007 |
Issuance (Retirement) of Stock, Net | 103.764 | 239.659 | 239.659 | 239.659 | 0.037 |
Issuance (Retirement) of Debt, Net | 0 | 0 | -11.483 | -11.483 | |
Net Change in Cash | 13.204 | 91.384 | 31.539 | 5.286 | 8.993 |
Deferred Taxes | 0 |
Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
---|---|---|---|---|---|---|
VR Adviser, LLC | Venture Capital | 6.8442 | 4563962 | 0 | 2022-09-30 | LOW |
RA Capital Management, LP | Hedge Fund | 6.596 | 4398453 | 0 | 2022-09-30 | LOW |
Foresite Capital Management, LLC | Private Equity | 6.0979 | 4066277 | 0 | 2022-09-30 | LOW |
BVF Partners L.P. | Hedge Fund | 5.9633 | 3976543 | 0 | 2022-09-30 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 5.9404 | 3961249 | 34100 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.8779 | 3919553 | 137723 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.1795 | 3453853 | -1447410 | 2022-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3819 | 2922013 | 115044 | 2022-09-30 | LOW |
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 4.1366 | 2758434 | 432934 | 2022-09-30 | LOW |
Commodore Capital LP | Hedge Fund | 3.615 | 2410622 | 0 | 2022-09-30 | MED |
Holocene Advisors, LP | Hedge Fund | 3.0906 | 2060918 | 0 | 2022-09-30 | HIGH |
Point72 Asset Management, L.P. | Hedge Fund | 2.7792 | 1853251 | 119351 | 2022-09-30 | HIGH |
Laurion Capital Management LP | Hedge Fund | 1.9565 | 1304624 | -135451 | 2022-09-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.9541 | 1303027 | 72786 | 2022-09-30 | LOW |
Walker Neal | Individual Investor | 1.8082 | 1205763 | -40000 | 2023-01-04 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.7773 | 1185178 | -144500 | 2022-09-30 | HIGH |
Fidelity Management & Research Company LLC | Investment Advisor | 1.7176 | 1145339 | -96969 | 2022-09-30 | LOW |
TCG Crossover Management, LLC | Investment Advisor | 1.717 | 1144939 | 0 | 2022-09-30 | MED |
Citadel Advisors LLC | Hedge Fund | 1.6772 | 1118417 | 165345 | 2022-09-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5427 | 1028723 | 71507 | 2022-09-30 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com GroupObchodníci
Aktívni klienti za mesia
Mesačný objem investícií
Výbery každý mesiac
Obchodná kalkulačka
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aclaris Therapeutics Inc Company profile
O spoločnosti Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. je biofarmaceutická spoločnosť v klinickej fáze, ktorá sa zameriava na vývoj liekov na liečbu imuno-zápalových ochorení. Spoločnosť sa zameriava na využitie svojich skúseností v oblasti objavovania a vývoja liekov a inhibície kináz na vývoj terapií malými molekulami na pomoc ľuďom postihnutým imuno-zápalovými ochoreniami. Kandidátmi na lieky spoločnosti sú zunsemetinib (ATI-450), ATI-1777 a ATI-2138. ATI-450, skúšaná perorálna zlúčenina malých molekúl selektívneho inhibítora MK2, určená na liečbu reumatoidnej artritídy. ATI-1777, skúšaná lokálna zlúčenina mäkkého inhibítora JAK 1/3, na liečbu atopickej dermatitídy. Spoločnosť sa zaoberá vývojom ATI-2138, skúmanej perorálnej inhibičnej zlúčeniny, ako potenciálnej liečby autoimunitných ochorení sprostredkovaných T-bunkami. Vyvíja tiež perorálne inhibítory JAK s predpojatosťou voči črevám ako potenciálnu liečbu zápalových črevných ochorení.
Industry: | Biotechnology & Medical Research (NEC) |
640 Lee Rd Ste 200
WAYNE
PENNSYLVANIA 19087-5636
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 485 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com